Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,499 across all filing types
Latest filing 2022-01-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
2021年度业绩预告
Regulatory Filings Classification · 95% confidence The document is a 2021 annual performance forecast (业绩预告) from Yifan Pharmaceutical Co., Ltd. It provides estimated net profit and earnings per share for the full year 2021, with a comparison to the prior year. It explicitly states that the forecast is preliminary, unaudited, and that the final audited data will be disclosed in the 2021 Annual Report. The document is short (780 characters) and serves as an earnings forecast announcement rather than a full financial report. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it an Earnings Release (ER) since it covers a full year forecast and is preliminary. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of earnings guidance and risk warning without substantive audited financial statements or detailed analysis.
2022-01-28 Chinese
关于全资子公司收到药品注册受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving a drug registration acceptance notice from the National Medical Products Administration (药品监督管理局). It details the drug registration application, product information, market data, R&D investment, and risk warnings. The document is short (1157 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report publication announcement since it does not mention an attached report or provide a link to a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a material event affecting the company.
2022-01-25 Chinese
关于对全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 亿帆医药股份有限公司 regarding the progress of providing a guarantee for its wholly-owned subsidiary 合肥亿帆生物医药有限公司. It details the guarantee contract, approval by the board and shareholders, financial data of the subsidiary, and compliance with regulatory requirements. The document is not a full financial report, audit report, or earnings release, but rather an update on a financing-related guarantee arrangement. It does not contain comprehensive financial statements or detailed financial analysis but focuses on the guarantee progress and related approvals. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2570 characters, which is consistent with an announcement rather than a full report.
2022-01-13 Chinese
关于全资子公司收到药品注册受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving a drug registration acceptance notice from the National Medical Products Administration (药监局). It details the drug name, registration application, regulatory acceptance, and related product information. The document is short (1123 characters) and serves as an official announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report itself but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-12 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving a drug registration certificate from the national drug regulatory authority. It details the drug name, registration number, approval date, and impact on the company. The document is short (1096 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-01-07 Chinese
关于2019年限制性股票激励计划预留授予部分第二个解除限售期解除限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the unlocking and listing of restricted shares under the company's 2019 restricted stock incentive plan. It includes extensive information about the stock incentive plan, the conditions for lifting restrictions, the number of shares involved, the dates of board meetings approving these actions, and legal opinions. The document is not a full financial report, audit report, or earnings release. It is not a proxy solicitation or AGM material. It is a regulatory announcement about the lifting of restrictions on shares granted under a stock incentive plan, including details on shareholding changes and legal compliance. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into more specific categories like Director's Dealing or Share Issue/Capital Change, and it is not a full report or financial statement. The document length (over 14,000 characters) and detailed content confirm it is not a mere report publication announcement but a substantive regulatory filing.
2022-01-06 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.